Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: APP009
MIFTS: 49

Appendix Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Appendix Adenocarcinoma

About this section

MalaCards integrated aliases for Appendix Adenocarcinoma:

Name: Appendix Adenocarcinoma 11 14 16
Adenocarcinoma of Appendix 71 33
Mucinous Adenocarcinoma 19 71
Cystadenocarcinoma 19 71
Adenocarcinoma of the Appendix 19
Colonic Type Adenocarcinoma 19
Appendiceal Adenocarcinoma 11
Nonmucinous Adenocarcinoma 19

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:3608
NCIt 49 C7718
SNOMED-CT 68 413445002
ICD11 33 1696330825
UMLS 71 C0007130 C0010631 C0238003
Sources

Summaries for Appendix Adenocarcinoma

About this section

GARD: 19 Cancer of the appendix is very rare and is typically found incidentally during appendectomies, in about 1% of the cases. According to a report published by the National Cancer Institute, using the Surveillance, Epidemiology, and End Results (SEER) database, appendix cancer account for about 0.4% of gastrointestinal tumors. There are several subytpes. The most common is the carcinoid type (66% of the total), with cyst-adenocarcinoma accounting for 20% and adenocarcinoma accounting for 10%. Then there are the rare forms of cancers which include adenocarcinoid, signet ring, non-Hodgkin's lymphoma, ganglioneuroma, and pheochromocytoma. Benign primary tumors are mainly 'mucinous epithelial neoplasms', also called adenomas, cystadenoma, and benign neoplastic mucocele. Adenocarcinoma of the appendix is a epithelial cancer of the appendix. The term 'epithelium' refers to cells that line hollow organs and glands and those that make up the outer surface of the body. Epithelial cells help to protect or enclose organs. Some produce mucus or other secretions.

MalaCards based summary: Appendix Adenocarcinoma, also known as adenocarcinoma of appendix, is related to endometrial mucinous adenocarcinoma and mucinous cystadenocarcinoma of pancreas. An important gene associated with Appendix Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are fMLP Pathway and Endometrial cancer. The drugs Etoposide and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include appendix, ovary and lymph node, and related phenotypes are Reduced mammosphere formation and Decreased viability in pancreas lineage

Disease Ontology: 11 An appendix carcinoma that derives from epithelial cells of glandular origin.
Sources

Related Diseases for Appendix Adenocarcinoma

About this section

Diseases related to Appendix Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 954)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 32.7 KRAS GNAS
2 mucinous cystadenocarcinoma of pancreas 32.5 SATB2 CEACAM5
3 bile duct mucinous adenocarcinoma 32.2 TP53 SYP
4 pancreatic serous cystadenocarcinoma 32.2 KRT7 KRT20 CEACAM5
5 pancreatic cystadenocarcinoma 32.2 SATB2 KRAS CEACAM5
6 acinar cell cystadenocarcinoma 32.1 SYP CHGA
7 bile duct cystadenocarcinoma 32.1 KRT7 KRT20 CEACAM5
8 ovarian mucinous adenocarcinoma 31.8 SATB2 KRT7 KRT20 CEACAM5 CDX2
9 ovarian serous cystadenocarcinoma 31.3 TP53 SMAD4 KRAS HRAS GNAS CEACAM5
10 papillary serous adenocarcinoma 31.2 TP53 KRT7 KRAS HRAS CEACAM5
11 anal fistula 31.1 KRT7 KRT20
12 renal pelvis adenocarcinoma 30.9 KRT7 CEACAM5
13 pseudomyxoma peritonei 30.8 TP53 KRT7 KRT20 KRAS GNAS CEACAM5
14 anus adenocarcinoma 30.7 KRT7 CDX2
15 mucinous lung adenocarcinoma 30.7 KRAS HRAS
16 carcinoid tumors, intestinal 30.6 SYP CHGA
17 thymus adenocarcinoma 30.5 KRT20 CEACAM5 CDX2
18 carcinoid syndrome 30.5 SYP CHGA
19 anal canal adenocarcinoma 30.4 KRT7 KRT20 CDX2
20 mammary paget's disease 30.3 KRT7 KRT20 CEACAM5
21 intestinal obstruction 30.3 KRT7 KRT20 CEACAM5 CDX2
22 obstructive jaundice 30.3 SYP KRT7 CEACAM5
23 mucinous adenocarcinoma 30.2 TP53 SMAD4 MSH6 KRT7 KRT20 KRAS
24 cystadenocarcinoma 30.2 TP53 KRT7 KRAS CEACAM5
25 peutz-jeghers syndrome 30.2 TP53 SMAD4 GNAS
26 bladder urachal carcinoma 30.2 KRT7 KRAS HRAS CDX2
27 endometrial adenocarcinoma 30.2 TP53 MSH6 KRT7 KRAS
28 nasal cavity adenocarcinoma 30.2 KRT7 HRAS CDX2
29 vulva adenocarcinoma 30.2 KRT7 KRT20 CEACAM5 CDX2
30 cecum adenocarcinoma 30.2 KRAS HRAS
31 hepatoid adenocarcinoma 30.2 KRT7 CEACAM5 CDX2
32 jejunal neoplasm 30.1 SYP KRT7
33 epididymis adenocarcinoma 30.1 KRT7 CDX2
34 clear cell adenocarcinoma 30.1 TP53 SMAD4 KRT7
35 ovarian cystadenoma 30.1 TP53 KRT7 CEACAM5
36 pancreatic adenocarcinoma 30.1 TP53 SMAD4 KRAS HRAS GNAS
37 diffuse gastric cancer 30.1 TP53 SMAD4 MSH6 KRAS
38 pancreatic serous cystadenoma 30.1 CHGA CEACAM5
39 goblet cell carcinoid 30.1 KRT20 CHGA
40 microcystic adenoma 30.1 SYP CHGA CEACAM5
41 bladder adenocarcinoma 30.1 TP53 KRT7 KRT20 CEACAM5 CDX2
42 mature teratoma of the ovary 30.1 SYP CEACAM5
43 microinvasive gastric cancer 30.0 TP53 CEACAM5 CDX2
44 thymus cancer 30.0 TP53 KRT7 HRAS
45 ovary adenocarcinoma 30.0 TP53 KRT7 KRAS HRAS GNAS CEACAM5
46 vulva cancer 30.0 TP53 KRT7 HRAS CEACAM5
47 benign mesothelioma 30.0 KRT7 KRT20 CEACAM5
48 struma ovarii 30.0 SYP KRT7 KRAS
49 transverse colon cancer 29.9 KRT20 KRAS HRAS CEACAM5
50 eyelid carcinoma 29.9 KRT7 KRT20

Graphical network of the top 20 diseases related to Appendix Adenocarcinoma:



Diseases related to Appendix Adenocarcinoma
Sources

Symptoms & Phenotypes for Appendix Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CHGA GNAS HRAS KRAS KRT7 SMAD4
2 Decreased viability in pancreas lineage GR00235-A 8.96 KRT7 TP53

MGI Mouse Phenotypes related to Appendix Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.06 CDX2 CEACAM5 GNAS HRAS KRAS MSH6
2 homeostasis/metabolism MP:0005376 10 CDX2 CEACAM5 CHGA GNAS HRAS KRAS
3 normal MP:0002873 9.98 CDX2 GNAS HRAS KRAS SMAD4 SYP
4 renal/urinary system MP:0005367 9.95 CHGA GNAS HRAS KRAS KRT7 SMAD4
5 muscle MP:0005369 9.91 CEACAM5 CHGA GNAS HRAS KRAS SMAD4
6 endocrine/exocrine gland MP:0005379 9.81 CDX2 CEACAM5 CHGA GNAS HRAS KRAS
7 limbs/digits/tail MP:0005371 9.8 CDX2 GNAS KRAS SATB2 SMAD4 TP53
8 digestive/alimentary MP:0005381 9.56 CDX2 CEACAM5 GNAS HRAS KRAS SATB2
9 craniofacial MP:0005382 9.1 GNAS HRAS KRAS SATB2 SMAD4 TP53
Sources

Drugs & Therapeutics for Appendix Adenocarcinoma

About this section

Drugs for Appendix Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
5
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
6
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
7
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
8
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
9
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
10
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
13
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
14
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
15
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
16
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
17
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
18
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
19
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
20
Tamoxifen Approved Phase 2, Phase 3 10540-29-1, 54965-24-1 2733526
21
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
23
Edrecolomab Investigational Phase 3 156586-89-9
24
Oregovomab Investigational Phase 3 213327-37-8
25
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
26
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-16-7, 110-17-8 444266 444972
27
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
28 Carotenoids Phase 3
29
Etoposide phosphate Phase 2, Phase 3 16760419
30 Formyltetrahydrofolates Phase 3
31 Tetrahydrofolates Phase 3
32 Adjuvants, Immunologic Phase 3
33 Immunoglobulins, Intravenous Phase 2, Phase 3
34 Immunoglobulin G Phase 2, Phase 3
35 Angiogenesis Inhibitors Phase 2, Phase 3
36 Immunologic Factors Phase 2, Phase 3
37 Endothelial Growth Factors Phase 2, Phase 3
38 Mitogens Phase 2, Phase 3
39 Anti-Bacterial Agents Phase 2, Phase 3
40 Albumin-Bound Paclitaxel Phase 2, Phase 3
41 topoisomerase I inhibitors Phase 2, Phase 3
42 Antimitotic Agents Phase 2, Phase 3
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
44 Tubulin Modulators Phase 2, Phase 3
45 Antibiotics, Antitubercular Phase 2, Phase 3
46 Liposomal doxorubicin Phase 2, Phase 3
47 Protein Kinase Inhibitors Phase 2, Phase 3
48 Cola Phase 3
49 Taxane Phase 3 108169
50 Hormones Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
3 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Unknown status NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
4 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
5 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
6 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
7 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
9 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
10 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
11 Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial) Recruiting NCT05601700 Phase 3 Letrozole tablets;carboplatin AUC 5 and paclitaxel 175 mg/m2
12 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
13 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
14 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
15 A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Recruiting NCT04498117 Phase 3 Paclitaxel;Carboplatin
16 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
17 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
18 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
19 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
20 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
21 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
22 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan;Trametinib Dimethyl Sulfoxide
23 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
24 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
25 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
26 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
27 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
28 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
29 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
30 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
31 A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer. Unknown status NCT01814501 Phase 2 irinotecan hydrochloride;fluorouracil;leucovorin calcium
32 A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) Unknown status NCT04446091 Phase 1, Phase 2 Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
33 A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Unknown status NCT03509246 Phase 2 Pegylated liposomal doxorubicin plus Bortezomib
34 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
35 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
36 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
37 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
38 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
39 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
40 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
41 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
42 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
43 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxaneâ„¢) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
44 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
45 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
46 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
47 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
48 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
49 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
50 A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum Completed NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate

Search NIH Clinical Center for Appendix Adenocarcinoma

Sources

Genetic Tests for Appendix Adenocarcinoma

About this section
Sources

Anatomical Context for Appendix Adenocarcinoma

About this section

Organs/tissues related to Appendix Adenocarcinoma:

MalaCards : Appendix, Ovary, Lymph Node, Liver, Breast, Colon, Pancreas
Sources

Publications for Appendix Adenocarcinoma

About this section

Articles related to Appendix Adenocarcinoma:

(show top 50) (show all 5399)
# Title Authors PMID Year
1
A massive malignant pleural effusion due to lung adenocarcinoma in an adult male: a case report. 62
36439928 2023
2
Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma. 62
36474376 2022
3
Mixed neuroendocrine/Non-neuroendocrine neoplasm (MiNEN) of gastrointestinal lineage arising in an ovarian mature cystic teratoma. 62
36388757 2022
4
NKX3.1 Expression in Salivary Gland "Intraductal" Papillary Mucinous Neoplasm: A Low-Grade Subtype of Salivary Gland Mucinous Adenocarcinoma. 62
35834096 2022
5
Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). 62
36367122 2022
6
Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea. 62
36345148 2022
7
High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action. 62
33630474 2022
8
Breast metastasis of signet ring cell carcinoma from the colon: a case report. 62
36451153 2022
9
Adult Colo-Colonic Intussusception in the Setting of Invasive Mucinous Adenocarcinoma: A Case Report. 62
36464886 2022
10
Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. 62
36258061 2022
11
Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification? 62
35794510 2022
12
Appendiceal mucinous adenocarcinoma masquerading as acute appendicitis. 62
35732542 2022
13
Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix. 62
36122512 2022
14
Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers. 62
36461012 2022
15
MUC6 distribution in the spectrum of pulmonary mucinous adenocarcinoma. 62
36071099 2022
16
Prevention of radiation enteritis by interposition of an intra-abdominal spacer before irradiation of an appendiceal tumour abscess drainage route. 62
35853802 2022
17
Defining the spatial landscape of KRAS mutated congenital pulmonary airway malformations: a distinct entity with a spectrum of histopathologic features. 62
35794233 2022
18
Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma. 62
36456172 2022
19
Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. 62
35879590 2022
20
Chronic expanding hematoma in the liver: a case report. 62
36414762 2022
21
Tumor Depth Prediction of Gastric Cancer With a T4 Score. 62
36340460 2022
22
The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. 62
36428700 2022
23
Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm. 62
36283994 2022
24
Cystadenocarcinoma of the intrahepatic bile duct in a dog. 62
36198612 2022
25
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion. 62
36436241 2022
26
A refined prediction of early recurrence combining tumor deposits in patients with resected rectal mucinous adenocarcinoma. 62
36357597 2022
27
Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. 62
35509235 2022
28
Neonatal congenital pulmonary airway malformation associated with mucinous adenocarcinoma and KRAS mutations. 62
34980466 2022
29
A prognostic nomogram for predicting overall survival in colorectal mucinous adenocarcinoma patients based on the SEER database. 62
36373623 2022
30
Colonic mucinous adenocarcinoma in a tufted deer: differential diagnosis and literature review. 62
36056527 2022
31
[A tumor of the uterus with a falsely benign aspect]. 62
35034828 2022
32
The appendix "mucocoele" misnomer: radiological terminology of "likely appendix mucinous neoplasm" better reflects pathology findings. 62
36411089 2022
33
Invasive Mucinous Adenocarcinoma of the Lung With a Mural Nodule-like Lesion. 62
35939825 2022
34
Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. 62
35590108 2022
35
Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. 62
36369472 2022
36
Extramural venous invasion and depth of extramural invasion on preoperative CT as prognostic imaging biomarkers in patients with locally advanced ascending colon cancer. 62
36066635 2022
37
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
38
Appendiceal adenocarcinoma presenting as a bladder tumor. 62
36275833 2022
39
Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma. 62
35945128 2022
40
Retroperitoneal mass, a rare manifestation of mucinous adenocarcinoma of appendix: A case report. 62
36415704 2022
41
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. 62
36376185 2022
42
Cystic Salivary Gland Neoplasms: Diagnostic Approach With a Focus on Ancillary Studies. 62
36044380 2022
43
A Case of Invasive Mucinous Adenocarcinoma with Acute Respiratory Distress Syndrome Diagnosed by Autopsy Findings. 62
36418103 2022
44
Patterns of Extrathoracic Metastasis in Lung Cancer Patients. 62
36421344 2022
45
[Relationship of diffusion kurtosis imaging parameters with the pathologic type and prognosis of rectal tumors]. 62
36380670 2022
46
High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses. 62
36330402 2022
47
Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis. 62
35768312 2022
48
Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 62
35852704 2022
49
Clinicopathological spectrums and prognosis of primary appendiceal adenocarcinoma, goblet cell adenocarcinoma, and low-grade appendiceal mucinous neoplasms. 62
36454563 2022
50
The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis. 62
36255176 2022
Sources

Variations for Appendix Adenocarcinoma

About this section
Sources

Expression for Appendix Adenocarcinoma

About this section
Search GEO for disease gene expression data for Appendix Adenocarcinoma.
Sources

Pathways for Appendix Adenocarcinoma

About this section

Pathways related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
fMLP Pathway 64
Show member pathways
 12.57 TP53 KRAS HRAS GNAS
2
Endometrial cancer 74
Show member pathways
 12.47 HRAS KRAS MSH6 SMAD4 TP53
3
Breast cancer pathway 74
Show member pathways
 12.23 TP53 SMAD4 KRAS HRAS
4
CCR3 Pathway in Eosinophils 64
Show member pathways
 11.93 KRAS HRAS GNAS
5
Epithelial to mesenchymal transition in colorectal cancer 74
11.91 TP53 SMAD4 KRAS HRAS
6
Integrated breast cancer pathway 74
11.85 TP53 SMAD4 MSH6 KRAS
7
Thermogenesis 74
Show member pathways
 11.81 KRAS HRAS GNAS
8
Gastrin signaling pathway 74
11.79 KRAS HRAS CHGA
9
Development EGFR signaling via small GTPases 22
Show member pathways
 11.78 KRAS HRAS GNAS
10
Senescence and autophagy in cancer 74
11.74 TP53 SMAD4 HRAS
11
mTOR Pathway 70
Show member pathways
 11.58 TP53 KRAS HRAS
12
DNA damage response (only ATM dependent) 74
11.47 TP53 SMAD4 KRAS HRAS
13
Serotonin HTR1 group and FOS pathway 74
Show member pathways
 11.44 KRAS HRAS GNAS
14
Colorectal Cancer Metastasis 64
11.24 TP53 SMAD4 MSH6 KRAS GNAS
15
Bladder cancer 74
11.21 TP53 KRAS HRAS
16
Transcription_Transcription factor Tubby signaling pathways 22
11.13 TP53 KRAS HRAS
17
Head and neck squamous cell carcinoma 74
11.12 TP53 SMAD4 KRAS HRAS
18
Envelope proteins and their potential roles in EDMD physiopathology 74
11.05 SMAD4 KRAS HRAS
19
Extracellular vesicle-mediated signaling in recipient cells 74
10.88 SMAD4 KRAS HRAS
20
TNF-alpha signaling pathway 74
Show member pathways
 10.6 KRAS HRAS
Sources

GO Terms for Appendix Adenocarcinoma

About this section

Biological processes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron apoptotic process GO:0051402 9.63 TP53 KRAS HRAS
2 intrinsic apoptotic signaling pathway GO:0097193 9.43 TP53 MSH6 HRAS
3 regulation of long-term neuronal synaptic plasticity GO:0048169 9.1 SYP KRAS HRAS
Sources

Sources for Appendix Adenocarcinoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....